Short Interest Worth Watching: What’s Propelling CALMARE THERAPEUTICS INCORPORATED (OTCMKTS:CTTC) After Lower Shorts Reported?

November 30, 2016 - By Ruchi Gupta   ·   0 Comments

Short Interest Worth Watching: What’s Propelling CALMARE THERAPEUTICS INCORPORATED (OTCMKTS:CTTC) After Lower Shorts Reported?

The stock of CALMARE THERAPEUTICS INCORPORATED (OTCMKTS:CTTC) registered a decrease of 50% in short interest. CTTC’s total short interest was 100 shares in November as published by FINRA. Its down 50% from 200 shares, reported previously. About 10,736 shares traded hands. Calmare Therapeutics Inc (OTCMKTS:CTTC) has declined 9.09% since April 27, 2016 and is downtrending. It has underperformed by 14.32% the S&P500.

Calmare Therapeutics Incorporated is a medical device company. The company has a market cap of $6.35 million. The Firm is engaged in developing and commercializing products and technologies for chronic neuropathic pain and wound care affliction patients. It currently has negative earnings. The Company’s medical device, the Calmare Pain Therapy Device (the Calmare Device), is a non-invasive and non-addictive modality that can treat chronic, neuropathic pain.

CTTC Company Profile

Calmare Therapeutics Incorporated (CTI), incorporated on August 12, 1971, is a medical device company. The Firm is engaged in developing and commercializing products and technologies for chronic neuropathic pain and wound care affliction patients. The Company’s medical device, the Calmare Pain Therapy Device (the Calmare Device), is a non-invasive and non-addictive modality that can treat chronic, neuropathic pain. The Company’s medical devices offer a non-pharmacological (no drugs), non-addictive (no narcotics) and non-invasive (over the skin) solution to chronic pain sufferers in an outpatient treatment setting. The Company’s subsidiary is Vector Vision, Inc.

More notable recent Calmare Therapeutics Inc (OTCMKTS:CTTC) news were published by: Businesswire.com which released: “Calmare Therapeutics Awarded $15 Million General Supply Order Contract” on February 18, 2016, also Businesswire.com with their article: “Calmare Therapeutics Incorporated Uplists” published on May 23, 2016, Businesswire.com published: “Calmare Therapeutics Discusses Complaint Settlement” on February 04, 2016. More interesting news about Calmare Therapeutics Inc (OTCMKTS:CTTC) were released by: Seekingalpha.com and their article: “Turnaround Strategy Being Implemented At Competitive Technologies” published on March 13, 2014 as well as Businesswire.com‘s news article titled: “ADDING MULTIMEDIA Calmare Therapeutics Incorporated Appoints Stephen J. D …” with publication date: September 15, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ruchi Gupta


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>